Pharmacoeconomic review report: Riociguat (Adempas)
Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1), as monotherapy or in combination with endothelin receptor antagonists (ERAs) in adult patients (≥ 18 years of age) with W...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario]
Canadian Agency for Drugs and Technologies in Health
December 2015, 2015
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references